Recruiting

Nicotinamide Riboside

Sponsor:

University of Pennsylvania

Code:

NCT07416786

Conditions

Healthy Adults

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Oral NR Supplementation

Study Details

Brief summary:

The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).

Conditions

Healthy Adults

Study ID

NCT07416786

Start date

Sep 1, 2026

Status verified date

Sep, 2026

Completion date

Jul 31, 2028

Anticipated

Primary completion date

Jul 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

  • Male or female age18-35 years or 70 years or older, healthy
  • if female reproductive potential, use of highly effective contraception (at least 1 month prior to screening and during study participation).
  • No known sensitivity to NR
  • No use of niacin, blood thinners or chemotherapy agents
  • HbA1c below 8.5% and not diabetec requiring insulin.
  • Not using/taking corticosteroids
  • No laboratory abnormalities indicating significant anemia, bleeding risk, kidney disease, or liver disease
  • No contraindication to MRI
  • Not Pregnant, lactating, or planning to become pregnant during participation
  • Not taking multivitamins or any over-the-counter supplements except calcium and vitamin D (any other supplements - discontinued 2 weeks prior to study participation).
  • not taking/ undergoing another investigational drug or other intervention within the past 30 days.

Study Design

Enrollment

48 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: NR Arm

All participants will receive NR 1000mg capsules to take by mouth daily for approximately 30 days.

Interventions

Oral NR Supplementation

Oral Nicotinamide Riboside (NR)

Primary outcome measure

  • Nicotinamide adenine dinucleotide (NAD) measurement in brain MRI [ Time Frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR) ]
  • NAD measurement of calf MRI [ Time Frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR) ]

Central Contacts and Locations

Central contacts

Damodar Reddy

215-898-9357cdamodar@pennmedicine.upenn.edu

Jordan Maddox, BA

215-898-3694jordan.maddox@pennmedicine.upenn.edu

Locations

Penn Medicine

Recruiting

Philadelphia, Pennsylvania, United States, 19104-6006

Contacts

Mark Elliott, Ph.D

215-898-8648melliott@upenn.edu

Damodar Reddy

215-898-9357cdamodar@pennmedicine.upenn.edu

More Information

Sponsor

University of Pennsylvania

Last update posted

Sep 11, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-12. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2026-09-11.